More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]
, 2018 © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M +6 more
core +3 more sources
Quality of Anticoagulation With Vitamin K Antagonists [PDF]
Clinical Cardiology, 2015 ABSTRACTBackgroundVitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in patients under VKA treatment in the prevention of stroke for atrial fibrillation (AF).HypothesisControl of anticoagulation with VKA is
Bertomeu-González, Vicente +9 more
openaire +5 more sources
Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]
, 2017 Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas +173 more
core +2 more sources
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020 Background The optimal antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention is a topic of debate. We aimed at defining the efficacy and safety of double antithrombotic therapy with single antiplatelet
D. Capodanno +9 more
semanticscholar +1 more source
Anticoagulants for acute ischaemic stroke [PDF]
, 2015 Peer reviewedPublisher ...
Counsell, Carl +2 more
core +1 more source
Smoothened adopts multiple active and inactive conformations capable of trafficking to the primary cilium. [PDF]
, 2009 Activation of Hedgehog (Hh) signaling requires the transmembrane protein Smoothened (Smo), a member of the G-protein coupled receptor superfamily. In mammals, Smo translocates to the primary cilium upon binding of Hh ligands to their receptor, Patched ...
Chen, Miao-Hsueh +2 more
core +3 more sources
British medical journal, 2017 Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant.
P. Nielsen +5 more
semanticscholar +1 more source
Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). [PDF]
, 2014 International audienceINTRODUCTION: In vitamin K antagonist (VKA)-treated patients with severe hemorrhage, guidelines recommend prompt VKA reversal with prothrombin complex concentrate (PCC) and vitamin K.
Benjamin Tremey +6 more
core +5 more sources
Lack of evidence does not justify neglect. how can we address unmet medical needs in calciphylaxis [PDF]
, 2016 Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a rare disease predominantly occurring in comorbidity with dialysis. Due to the very low frequency of CUA, prospective studies on its management are lacking and even anecdotal reports on ...
Brandenburg, Vincent Matthias +14 more
core +1 more source
European Heart Journal, 2018 Aim The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion.
M. Ezekowitz +10 more
semanticscholar +1 more source